Johnson & Johnson received FDA approval for its Dual Energy THERMOCOOL SMARTTOUCH SF Platform on July 8, 2026.
The integrated catheter ablation solution allows electrophysiologists to use either radiofrequency (RF) or pulsed field (PF) energy through a single catheter. This dual-energy capability provides greater versatility when treating complex cardiac arrhythmia cases.
The system integrates with the CARTO ecosystem to offer advanced mapping and guidance to physicians. This technology builds upon the existing THERMOCOOL SMARTTOUCH SF Platform within the company's MedTech division.
The approval aims to enhance patient treatment options and solidify Johnson & Johnson’s position in the global electrophysiology market.